Tebentafusp-tebn is approved for unresectable or metastatic uveal melanoma

Share This Post

March 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has been licenced by the Food and Drug Administration for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

IMCgp100-202 (NCT03070392), a randomised, open-label, multicenter trial of 378 patients with metastatic uveal melanoma, was used to assess efficacy. HLA-A*02:01 genotype positivity was necessary, as determined by a central assay. Patients were excluded if they had had prior systemic or localised liver-directed treatment. Prior oligometastatic illness surgical resection was allowed. Patients with clinically severe heart disease or untreated symptomatic brain metastases were excluded from the study.

Tebentafusp-tebn (N=252) or investigator’s choice (N=126) of pembrolizumab, ipilimumab, or dacarbazine were given to patients in a 2:1 ratio. Tebentafusp-tebn was given as an intravenous infusion every week at a dose of 20 mcg on day 1, 30 mcg on day 8, 68 mcg on day 15, and every consecutive week until disease progression or intolerable toxicity. Overall survival was the primary efficacy outcome measure (OS). Investigator-assessed progression-free survival (PFS) using RECIST 1.1 was another efficacy endpoint. Patients treated with tebentafusp-tebn had a median OS of 21.7 months (95 percent CI: 18.6, 28.6), compared to 16 months (95 percent CI: 9.7, 18.4) in the investigator’s choice arm (HR=0.51, 95 percent CI: 0.37, 0.71, p0.0001). PFS for those taking tebentafusp-tebn was 3.3 months (95 percent CI: 3, 5) and 2.9 months (95 percent CI: 2.8, 3) in the investigator’s choice arm (HR=0.73, 95 percent CI: 0.58, 0.94, p=0.0139).

Cytokine release syndrome, rash, pyrexia, pruritus, exhaustion, nausea, chills, abdominal discomfort, edoema, hypotension, dry skin, headache, and vomiting were the most prevalent side effects (30%). Reduced lymphocyte count, increased creatinine, increased glucose, increased aspartate aminotransferase, increased alanine aminotransferase, decreased haemoglobin, and decreased phosphate were the most prevalent laboratory abnormalities (50 percent).

The recommended tebentafusp-tebn dose administered intravenously is:

  • 20 mcg on day 1,
  • 30 mcg on day 8,
  • 68 mcg on day 15, and
  • 68 mcg once weekly thereafter.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

The future of gene therapy for genetic disorders
Treatment

Unlocking the genetic code: The future of gene therapy for genetic disorders

Gene therapy has typified the revolution in medicine that gives hope to various genetic disorders. This advanced treatment stops, and sometimes even reverses, the progress of a disease by the direct repair and replacement of defective genes. Trials and ethical dilemmas aside, this talent for transformation puts gene therapy right at the threshold of new frontiers in genetic medicine where inherited diseases might be eradicated altogether someday.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy